Central Nervous System Therapeutic Market
Central Nervous System Therapeutic Market Size, Share and Trends Analysis Report, By Indication (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, and Cancer), By Application (Hospital and Clinic, Homecare, and Others), By Drug Class (Immunomodulatory Drugs, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Antidepressants, and Others), Forecast Period (2022-2028)
Central nervous system therapeutic (CNS) market is anticipated to grow at a CAGR of 7.5% during the forecast period. Central nervous system disorder is a neurological disease that directly affects the functioning of the brain or spinal cord and other body parts. Stroke, Alzheimer's Disease, spinal cord disorders, and Parkinson's disease are some common central nervous system disorders. The rising prevalence of Parkinson’s disease across the globe is contributing to the growth of the global central nervous system therapeutics market. According to the data provided by Parkinson's Foundation, around 1 million people in the US have Parkinson's disease, and also it is expected to rise to 1.2 million by 2030. Additionally, every year in the US around 60,000 people are diagnosed with this disease. This, in turn, is driving the demand for medications used for the treatment of Parkinson’s diseases and thereby driving the market growth.
Segmental Outlook
The global central nervous system therapeutic market is segmented based on indication, application, and drug class. Based on the disease, the market is segmented into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, infectious diseases and cancer. Based on the application, the market is segmented into hospital & clinics, homecare, and others. Based on drug class, the market is segmented into immunomodulatory drugs, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, and others. The above mentioned segments can be customized as per the requirements.
Neurodegenerative Diseases Segment to Witness Significant Share in the Market During the Forecast Period
Based on indication, the neurodegenerative disease segment is expected to hold a significant share in the market during the forecast period. The increasing neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, spinal muscular atrophy, and others are expected to drive the neurodegenerative diseases segment. These diseases are incurable and cause problems with mental functioning, movement and ability to speak and breathe. According to the Centers For Disease Control and Prevention (CDC), in 2020 there were 5.8 million people in the US having Alzheimer’s disease and is expected to nearly triple to 14 million people by 2060. This, in turn, is accelerating the demand for the treatment of Alzheimer’s diseases and thereby driving the market growth.
Regional Outlook
The global central nervous system therapeutic market is segmented based on geography including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed for a particular region or country level as per the requirement. North America region holds a significant share in the global CNS therapeutic market, owing to the presence of strong players in the region and the R&D initiatives taken by key players to develop new therapies for different central nervous system disorders. This shows the increasing demand for the CNS therapeutics market in the North America region. Moreover, several awareness campaigns about the treatment and diagnosis of CNS diseases are further boosting the market growth in the region.
Global Central Nervous System Therapeutic Market Growth, by Region 2022-2028
Asia-Pacific to Witness Considerable Share in the Market During The Forecast Period
Asia-Pacific is expected to hold a potential share in the global central nervous systems therapeutic market across the globe. Owing to a large number of patients related to these nervous system diseases is boosting the market growth. According to Narayana Health.org, India has around 7 million elders affected with Parkinson’s disease. This shows the rising prevalence of disease in the region and thereby driving the demand for CNS therapies for the management of these disorders.
Market Players Outlook
The major companies operating in the global central nervous system therapeutic market include Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Biogen Inc., and Eli Lilly, and Company Inc. The market players are contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, and new product launches, to stay competitive in the market. For instance, in March 2021, Janssen Pharmaceutical Companies of Johnson & Johnson Services Inc. received USFDA approval and launched an oral drug for the treatment of adults with relapsing forms of multiple sclerosis named Ponvory.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global central nervous system therapeutic market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Recovery Scenario of Global Central Nervous System Therapeutic Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Johnson & Johnson Services Inc.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Merck & Co. Inc.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Novartis AG
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Biogen Inc.
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Eli Lilly and Company Inc.
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Segmentation
4.1. Global Central Nervous System Therapeutics Market by Indication
4.1.1. Neurovascular Diseases
4.1.2. CNS Trauma
4.1.3. Mental Health
4.1.4. Neurodegenerative Diseases
4.1.5. Infectious Diseases
4.1.6. Cancer
4.2. Global Central Nervous System Therapeutic Market by Application
4.2.1. Hospitals and Clinics
4.2.2. Homecare
4.2.3. Others
4.3. Global Central Nervous System Therapeutic Market by Drug Class
4.3.1. Immunomodulatory Drugs
4.3.2. Interferons
4.3.3. Decarboxylase Inhibitors
4.3.4. Dopamine Agonists
4.3.5. Antidepressants
4.3.6. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AstraZeneca plc
6.2. Cipla Ltd.
6.3. CNS Pharmaceuticals, Inc.
6.4. F. Hoffmann-La Roche Ltd.
6.5. GlaxoSmithKline plc
6.6. H. Lundbeck A/S
6.7. Lupin Ltd.
6.8. Medopharm Private Ltd.
6.9. Neurelis, Inc.
6.10. Nuventra Pharma Sciences
6.11. Otsuka Pharmaceutical Co., Ltd.
6.12. Pfizer Inc.
6.13. Sanofi S.A.
6.14. Shire plc
6.15. Teva Pharmaceutical Industries Ltd.
1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEUROVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CNS TRAUMA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR MENTAL HEALTH MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEURODEGENERATIVE DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOMECARE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
13. GLOBAL IMMUNOMODULATORY DRUGS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL INTERFERONS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. GLOBAL DECARBOXYLASE INHIBITORS CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
16. GLOBAL DOPAMINE AGONISTS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
17. GLOBAL ANTIDEPRESSANTS CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
18. GLOBAL OTHER DRUG CLASS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
20. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
22. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
23. NORTH AMERICAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
24. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
25. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
26. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
27. EUROPEAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
28. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
29. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
30. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
31. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
32. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
33. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
34. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
35. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
1. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEURODEGENERATIVE DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
2. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY INDICATION, 2021 VS 2028 (%)
3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEUROVASCULAR DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CNS TRAUMA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR MENTAL HEALTH MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR NEURODEGENERATIVE DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR INFECTIOUS DISEASES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOSPITAL & CLINIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR HOMECARE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC FOR OTHERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY DRUG CLASS, 2021 VS 2028 (%)
14. GLOBAL IMMUNOMODULATORY DRUGS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL INTERFERONS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. GLOBAL DECARBOXYLASE INHIBITORS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
17. GLOBAL DOPAMINE AGONISTS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
18. GLOBAL ANTIDEPRESSANTS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
19. GLOBAL OTHER DRUG CLASS FOR CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
21. US CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
22. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
23. UK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
24. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
25. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
26. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
27. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF EUROPE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
29. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
30. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
31. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
32. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
33. REST OF ASIA-PACIFIC CENTRAL NERVOUS SYSTEMTHERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
34. REST OF THE WORLD CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
